E-LIB Suche - Ergebnisse für: Locke, F.L.

1

DURABLES RESPONSES WITH ANTI‐CD19 ALLOGENEIC CAR T ALLO‐501..:

Locke, F. L. ; Lekakis, L. ; Eradat, H....
Hematological Oncology. 41 (2023) S2 - p. 85-86 , 2023

Link: https://doi.org/10.1002/..

2

PRIMARY OVERALL SURVIVAL ANALYSIS OF THE PHASE 3 RANDOMIZED..:

Westin, J. R. ; Oluwole, O. O. ; Kersten, M. J....
Hematological Oncology. 41 (2023) S2 - p. 52-54 , 2023

Link: https://doi.org/10.1002/..

3

SEVERE HEMATOLOGICAL TOXICITY FOLLOWING CD19 CAR‐T FOR RELA..:

Rejeski, K. ; Perez, A. ; Iacoboni, G....
Hematological Oncology. 41 (2023) S2 - p. 204-204 , 2023

Link: https://doi.org/10.1002/..

4

EE229 Cost-Effectiveness of Axicabtagene Ciloleucel and Tis..:

Locke, F.L. ; Ray, M. ; Bradford, R....
Value in Health. 26 (2023) 12 - p. S95 , 2023

Link: https://doi.org/10.1016/..

5

Real‐world outcomes of brexucabtagene autoleucel (brexu‐cel..:

Ahmed, N. ; Kambhampati, S. ; Hamadani, M....
Hematological Oncology. 41 (2023) S2 - p. 488-490 , 2023

Link: https://doi.org/10.1002/..

6

P505 Serum pretreatment and the single antigen bead assay –..:

Locke, A.F. ; Gjertson, D. ; Reed, E.F..
Human Immunology. 84 (2023) - p. 128 , 2023

Link: https://doi.org/10.1016/..

7

Patient-Level Disease Burden as a Predictor of In-Field Fai..:

Figura, N.B. ; Sim, A.J. ; Chavez, J.C....
International Journal of Radiation Oncology*Biology*Physics. 114 (2022) 3 - p. S85 , 2022

Link: https://doi.org/10.1016/..

8

P1155: BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MA..:

Wang, Y. ; Jain, P. ; Locke, F....
HemaSphere. 6 (2022) - p. 1042-1043 , 2022

Link: https://doi.org/10.1097/..

9

P1117: THREE-YEAR FOLLOW-UP OF OUTCOMES WITH KTE-X19 IN PAT..:

Wang, M. L. ; Munoz, J. ; Goy, A....
HemaSphere. 6 (2022) - p. 1007-1008 , 2022

Link: https://doi.org/10.1097/..

10

S211: CLINICAL AND PATIENT-REPORTED OUTCOMES IN A PHASE 3 S..:

Sureda, A. ; Westin, J. ; Locke, F. L....
HemaSphere. 6 (2022) - p. 112-113 , 2022

Link: https://doi.org/10.1097/..

11

P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSE..:

Bücklein, V. ; Perez, A. ; Iacoboni, G....
HemaSphere. 6 (2022) - p. 1330-1331 , 2022

Link: https://doi.org/10.1097/..

12

Oral Mucosal Sparing in High-Dose Total Body Irradiation (T..:

Liveringhouse, C. ; Sandoval, M.L. ; Dohm, A.E....
International Journal of Radiation Oncology*Biology*Physics. 114 (2022) 3 - p. e353 , 2022

Link: https://doi.org/10.1016/..

13

P1198: ASSOCIATION OF PRETREATMENT TUMOR CHARACTERISTICS AN..:

Locke, F. L. ; Chou, J. ; Vardhanabhuti, S....
HemaSphere. 6 (2022) - p. 1084-1085 , 2022

Link: https://doi.org/10.1097/..

14

P1454: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BR..:

Locke, F. ; Hu, Z.-H. ; Gerson, J....
HemaSphere. 6 (2022) - p. 1336-1337 , 2022

Link: https://doi.org/10.1097/..

15

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT ..:

Rejeski, K. ; Albanyan, O. ; Iacoboni, G....
HemaSphere. 6 (2022) - p. 1340-1341 , 2022

Link: https://doi.org/10.1097/..